Clinical Trial Update: Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers [Phase 1, Phase 2]

View source ↗

Summary

The document describes an ongoing Phase 1/2 trial evaluating tivozanib for biliary tract cancers and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Tivozanib (tivozanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cholangiocarcinoma, Bile Duct Neoplasm | Phase 1, Phase 2 | Status: RECRUITING